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Aims: Cardiovascular (CV) disease is a major cause of reduced life expectancy in type 1 diabetes
(T1D). Intensive insulin therapy prevents CV complications but is constrained by hypoglycaemia
and weight gain. Adjunct metformin reduces insulin dose requirement and stabilizes weight but
there are no data on its cardiovascular effects. We have therefore initiated an international
double-blind, randomized, placebo-controlled trial (REMOVAL: REducing with MetfOrmin Vas-
cular Adverse Lesions in type 1 diabetes) to examine whether metformin reduces progression
of atherosclerosis in adults with T1D. Individuals ≥40 years of age with T1D for ≥5 years are
eligible if they have ≥3 of 10 specified CV risk factors. The enrolment target is 500 participants
in 17 international centres.
Materials and methods: After 12 weeks of single-blind placebo-controlled run-in, participants
with ≥ 70% adherence are randomized to metformin or matching placebo for 3 years with insu-
lin titrated towards HbA1c 7.0% (53 mmol/mol). The primary endpoint is progression of aver-
aged mean far wall common carotid intima-media thickness (cIMT) measured by
ultrasonography at baseline, 12, 24 and 36 months. This design provides 90% power to detect
a mean difference of 0.0167 mm in cIMT progression between treatment arms (α = 0.05),
assuming that up to 20% withdraw or discontinue treatment. Other endpoints include HbA1c,
weight, LDL cholesterol, insulin requirement, progression of retinopathy, endothelial function
and frequency of hypoglycaemia.
Conclusion: REMOVAL is the largest clinical trial of adjunct metformin therapy in T1D to date
and will provide clinically meaningful information on its potential to impact CV disease and
other complications.
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endothelial function, hypoglycaemia metformin, type 1 diabetes, weight
Received: 23 August 2016 Revised: 18 November 2016 Accepted: 29 November 2016
DOI 10.1111/dom.12840
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is
properly cited.
© 2016 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
Diabetes Obes Metab. 2017;19:509–516. wileyonlinelibrary.com/journal/dom 509
1 | INTRODUCTION
Period life expectancy in people with type 1 diabetes (T1D) is
reduced by 11 to 13 years1; rates of CV events are at least double
those in the general population and account for approximately 45%
of deaths.2 Long-term post-randomization data from the Diabetes
Control and Complications Trial (DCCT) participants followed up in
the Epidemiology of Diabetes Interventions and Complications (EDIC)
study demonstrate that intensive blood glucose control reduces both
microvascular and CV complications in T1D.3
However, in population-based data only approximately 30% of
individuals with T1D are near target HbA1c (<7.5%/59 mmol/mol)
and at least 30% have poor control (HbA1c ≥ 9.0%/75 mmol/mol).4
A key barrier to optimizing glycaemia is hypoglycaemia; in the DCCT,
rates of severe hypoglycaemia were 3-fold higher in those rando-
mized to intensive therapy and with HbA1c at or below target.5
Another long-term issue is insulin-induced weight gain, which may be
accompanied by escalating insulin dose requirements, increased LDL
cholesterol and/or raised blood pressure (BP).6–8
Adjunct therapy with metformin reduces insulin dosage in T1D
and may attenuate weight gain9–13; some clinicians already use it in
this context. As metformin reduces CV disease in type 2 diabetes
(T2D),14–16 and is recommended first-line therapy in most interna-
tional guidelines,17 we hypothesized that it might also provide CV
protection in T1D.
In this largest and longest trial of metformin in T1D to date, we
aim to gather data on cardiovascular and metabolic endpoints as well
as key aspects of long-term safety (eg, vitamin B12 status, lactic aci-
dosis). Progression of carotid artery intima-media thickness (cIMT)
measured by ultrasonography is the primary endpoint as it was
reduced by intensive glucose control in DCCT-EDIC18; this was later
validated by reduced CV events.3
2 | MATERIALS AND METHODS
2.1 | Objectives and endpoints
The primary objective of the REducing with MetfOrmin Vascular
Adverse Lesions in type 1 diabetes (REMOVAL: clinical trials.gov
NCT01483560) is to test in adults with T1D whether metformin added
to insulin therapy (titrated towards target HbA1c 7.0%/53 mmol/mol)
reduces progression of atherosclerosis in the common carotid artery
(CCA), defined as within-person change in bilateral averaged mean far
wall carotid intima-media thickness (cIMT) measured annually over
3 years.
For measurement of cIMT, the same ultrasound system and pre-
set image parameter settings (eg, depth, gain, persistence, dynamic
range, post processing) are to be maintained at each site throughout
the study. The reading centre (University College London [UK]) trains
each site sonographer who then submits 5 accreditation scans. Right
and left carotid arteries are interrogated in B mode with a 7.0 MHz
or higher broadband linear array transducer with concurrent record-
ing of a three lead ECG. A plaque screen (defined as focal thickening
≥1.5 mm or 50% greater than surrounding IMT) of the near and far
walls of the CCA, bulb and internal carotid artery segments is per-
formed also. Longitudinal images of the CCA are obtained at anterior,
lateral and posterior angles using Meijer’s arc during at least 5 cardiac
cycles. Additional cIMT measurements are performed on a panel of
6 participants at each site annually to monitor reproducibility. At the
reading centre, triplicate measurements are taken from the distal cen-
timetre of the CCA (ie, immediately proximal to the bulb) by a single
trained assessor using a validated semi-automated program.19 The
assessor undergoes repeated “masked” QC cycles to assess
repeatability.
For the assessment of retinal disease, 2 colour 45 field photo-
graphs (field 1, optic disc; field 2, macula) are taken in each eye at
randomization and at 36 months. In the UK these are acquired
directly from national retinal screening systems. Images are graded
using custom-designed software at the University of Wisconsin Ocu-
lar Epidemiology Reading Center (OERC) using the modified Airlie
House classification scheme and the Early Treatment Diabetic Reti-
nopathy Study severity scale as previously described.20 Component
retinal lesions are evaluated individually. If significant retinal pathol-
ogy exists, the site principal investigator is notified to ensure appro-
priate clinical action.
Endothelial function is assessed in centres covering 80% of parti-
cipants using peripheral Arterial Tonometry (ENDOPAT, Itamar, Israel)
to measure Reactive Hyperaemia Index (RHI) non-invasively at
0, 12 and 36 months. This method assesses changes in digital pulse
volume and pulse wave velocity.21 ENDOPAT studies are reviewed
by Itamar staff and scan quality reported back to site staff within
1 week.
Other secondary and tertiary endpoints are shown in Table 1.
Each of the secondary outcome measures will be analysed separately
and the individual results will be reported. The protocol has a pre-
defined composite interpretation of the secondary outcomes where
results will be considered clinically meaningful with the potential to
influence clinical practice in the event that a statistically significant
improvement in 2 or more of the following individual outcomes is
observed on metformin: (1) HbA1c (by DCCT-standardized local
assays); (2) LDL-cholesterol (centrally-measured); (3) albuminuria,
based on at least 2 separate urine specimens and routinely available
assays (File S1, Appendix 3; (4) 2 or more step progression on the 11-
step modified concatenated retinopathy severity scale; (5) weight, by
calibrated scales; (6) insulin dose; and (7) endothelial function (RHI).
2.2 | Trial management
The protocol was approved by the West of Scotland Research Ethics
Service (REC1) (UK) and the following Medical Research Ethics Com-
mittees/Institutional Review Boards: St Vincent’s Hospital and Royal
Melbourne Hospital (Melbourne) and Royal Prince Alfred Hospital
(Sydney, Australia; Western University Health Science Research Eth-
ics Board (Canada); Hovedstaden Region Centre of Health (Denmark);
and Maastricht University Medical Centre, (Netherlands). Trial gov-
ernance and oversight is the responsibility of the co-sponsors
(University of Glasgow and Greater Glasgow and Clyde Health Board,
UK) with trial monitoring outside the UK and Denmark delegated by
agreement to national partner institutions. Active and matching
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placebo study medications are provided free of charge by Merck
KGaA (Darmstadt, Germany). All scans and photographs are uploaded
by site personnel via a purpose-designed electronic Case Report
Form (eCRF) on to a secure server at the University of Glasgow for
digital archiving and subsequent download for analysis at reading
centres. Data management is by the Robertson Centre for Biostatis-
tics, University of Glasgow. An Independent Data Monitoring Com-
mittee (IDMC) reviews 6-monthly unmasked reports on study
progress. Seventeen initial and 5 reserve sites with expertise in cIMT
measurement have been selected across the UK, Australia, Canada,
Denmark and the Netherlands. Where long-term post-randomization
follow-up is permitted, we seek consent from participants for the
local team to remain in contact at trial end.
2.3 | Screening, eligibility, enrolment and run-in
period
Individuals aged ≥40 with ≥5 years T1D and at least 3 of 10 specified
CV risk factors are eligible (Table 2). T1D is defined as diagnosis of
diabetes before age 35 years and insulin use within 1 year. Potential
TABLE 1 Study endpoints
Change from baseline compared between treatment groups:
Primary
Progression of averaged mean far wall common carotid artery IMT (CCA cIMT, measured in mm, at baseline, 12, 24 and 36 months).
Secondary
1. HbA1c (site DCCT-aligned laboratories)
2. LDL-cholesterol (central lab)
3. Albuminuria1
4. Retinopathy stage (2-step progression on the ETDRS scale)
5. Weight
6. Insulin dose
7. Endothelial function (in at least 80% of participants)
Composite interpretation of all secondary endpoints
Improvement in 2 or more of these secondary endpoints will be considered clinically meaningful with the potential to influence clinical practice.
Tertiary
1. Frequency of hypoglycaemia (modified Steno Hypoglycaemia Questionnaire)
2. Treatment satisfaction (Diabetes Treatment Satisfaction Questionnaire)
3. Markers of endothelial function (t-PA, sE-selectin, sICAM-1)
4. Progression of averaged maximal distal common carotid artery IMT (CCA cIMT, measured in mm, at baseline, 12, 24 and 36 months).
5. Vitamin B12 status
1 Time to event analysis using a Cox Proportional Hazards Model.
TABLE 2 Entry criteria1
Inclusion Exclusion
Type 1 diabetes for 5 years or more2 1. eGFR < 45 mL/min/1.73 m2
2. Woman of childbearing age not using effective contraception
3. Pregnancy and/or lactation
4. Acute Coronary Syndrome or Stroke/TIA within the last 3 months
5. NYHA stage 3 or 4 heart failure
6. Uncontrolled angina
7. Significant hypoglycaemia unawareness6
8. Impaired cognitive function/unable to give informed consent
9. Previous carotid surgery/inability to capture adequate carotid images
10. Gastroparesis6
11. History of lactic acidosis
12. Other contraindications to metformin
 Hepatic impairment
 Known hypersensitivity to metformin
 Acute illness (dehydration, severe infection, Shock, acute cardiac failure)
 Suspected tissue hypoxia
13. Any co-existent life threatening condition including prior diagnosis of
cancer within 2 years
14. History of alcohol problem or drug abuse
Age ≥ 40 years
7.0 ≤ HbA1c < 10.0% (53-86 mmol/mol)
AND
3 or more of the following 10 CVD risk factors
1. BMI ≥ 27 kg/m2
2. Current HbA1c > 8.0% (64 mmol/mol)
3. Known CVD/peripheral vascular disease
4. Current smoker
5. eGFR < 90 mL/min/1.73 m2
6. Confirmed micro- (or macro-) albuminuria3
7. Hypertension (BP ≥ 140/90 mm Hg; or established
antihypertensive treatment)
8. Dyslipidaemia4
9. Strong family history of CVD5
10. Duration of diabetes >20 years
1 Abbreviated from full Protocol Version 1.0.
2 Defined as diagnosis below age 35 years AND insulin use within 1 year of diagnosis.
3 As judged by the site principal investigator based on at least 2 urine samples assayed locally and interpreted according to site reference ranges (File S1,
Appendix 3).
4 Total cholesterol ≥5.0 mmol/L (200 mg/dL); or HDL cholesterol <1.2 mmol/L (46 mg/dL) [men] or <1.3 mmol/L (50 mg/dL) [women]; or triglycerides
≥1.7 mmol/L (150 mg/dL); or established on lipid-lowering treatment.
5 At least one parent, biological aunt/uncle, or sibling with myocardial infarction, or stroke aged <60 years).
6 Confirmed as significant by site principal investigator.
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participants are approached by mail or personally at regular clinic vis-
its; those expressing an interest are given further information and
invited to return to a (non-fasting) screening visit.
Following informed consent, past medical history, family history
and concomitant medication (including duration, type and dose of
any previous statin and/or ACE inhibitor therapy) are recorded on
the eCRF. Height, body weight, ethnicity and smoking status are
documented; blood pressure (BP) and heart rate are measured in trip-
licate according to Standard Operating Procedures specified in the
protocol. The Steno Hypoglycaemia questionnaire (File S1) and the
Diabetes Treatment Satisfaction Questionnaire (DTSQ)22 are adminis-
tered. Blood and urine samples are sent to local laboratories for
measurement of HbA1c, serum lipids, liver function tests, albuminu-
ria, renal function (unless results are available from the previous
90 days) and random C-peptide. Aliquots of serum, plasma, urine and
buffy coat are retained for biomarker assays and later DNA extrac-
tion. Cholesterol and BP lowering therapies are reviewed against local
standard of care and treatment adjusted as indicated. Urine for preg-
nancy testing is requested from women of childbearing potential who
are not using an effective method of contraception at this (and all
subsequent) in-person visits, with a view to discontinuing study medi-
cation if the test is positive.
Enrolled participants are invited to enter a 3-month run-in period
and receive single-blind placebo tablets (matching metformin 500 mg)
to take once daily with the evening meal during the third month only
(Figure 1). The first of a series of dedicated study diaries is provided,
containing guidance on study medication dose titration, adverse
effects and “sick day rules” as well as contact details for the local
study team. Space is provided for structured recording of insulin
doses and 4-point blood glucose profiles during 3 days prior to each
scheduled telephone or in-person visit. Participants are also asked to
record all changes in concomitant medication.
Individual insulin regimens are reviewed by site staff at the
beginning of the run-in period with a view to making any changes
required to facilitate optimisation of control (target HbA1c 7.0%/
53 mmol/mol). Additional in-person clinical visits are arranged if nec-
essary. Structured telephone visits are conducted approximately
monthly during the remainder of the run-in, for review of blood glu-
cose monitoring data and insulin doses; this support remains available
throughout the trial.
2.4 | Randomization and follow-up
A randomisation visit (fasting) is scheduled at the end of the run-in
period. Participants with ≥70% adherence and a screening visit C-
peptide ≤0.2 nmol/L undergo baseline study measurements including
cIMT, endothelial function and retinal photographs. Randomization is
by an Interactive Voice Response System (IVRS) hosted by the
Robertson Centre for Biostatistics. Double-blind study medication
(metformin as Glucophage 500 mg or matching placebo) is issued in
identical packages covering 3- or 6-month periods according to the
visit schedule.
Participants are asked to carry a Patient Alert Card containing
details of emergency unmasking procedures. Following randomiza-
tion, they are asked to up-titrate their dose of study medication on a
weekly basis from 1 tablet daily with the evening meal in week 1, to
2 tablets per day (with breakfast and evening meal) in week 2, until
the target dose of 2 tablets with each of these meals (equivalent to
1000 mg twice daily) is achieved in week 4. Dose titration is sup-
ported by weekly telephone visits; dose down-titration or treatment
interruption (eg, in response to gastrointestinal adverse effects) is
permitted at any time during the trial. If treatment interruption per-
sists for more than 4 weeks, site staff are instructed to record a per-
manent treatment discontinuation. Treatment restart is encouraged
at any time, if appropriate, at the discretion of the site principal inves-
tigator. Current dose is recorded at each in-person visit with tablet
counts conducted by site staff.
As far as possible, study visits are designed to coincide with
appointments in routine care; repeat assessments of the main study
endpoints and other items are conducted at 12, 24 and 36 months
FIGURE 1 Outline of protocol.
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(Table 3). During the trial, all participants continue to have access to
the usual local arrangements for diet and lifestyle advice, along with
weight management. Ongoing glycaemia, BP and cholesterol manage-
ment are under the care of the site PI and the usual care team,
according to updated national and international guidelines.
2.5 | Hypoglycaemia
Participants are asked to record all symptomatic or biochemically-
proven hypoglycaemic episodes (<2.8 mmol/L; 50 mg/dL) in the
study diary. This information is used by site nurses at follow-up visits
as a basis for completing the Steno Hypoglycaemia Questionnaire in
which events are categorized as: minor (self-treated, resolved with
short acting glucose and longer acting carbohydrate); major (requiring
assistance from 1 or more other persons); or major with unconscious-
ness (self-reported).
2.6 | Safety and pharmacovigilance
Hepatic and renal function is monitored at all in-person visits. Perma-
nent discontinuation of study medication is mandated in cases of sig-
nificant hepatic impairment (alanine transaminase >3.0 times upper
limit of normal) or renal impairment (eGFR < 30 mL/min/1.73 m2).
Investigators are advised to reduce the study medication dose to
1 tablet twice daily in all participants in whom eGFR falls below
45 mL/min/1.73 m2 during follow-up. Serum lactate is checked at
baseline and annually; study medication is permanently discontinued
if a single measurement is >5.0 mmol/L with acidosis (including rou-
tine clinical care) or if a level >3.0 mmol/L is sustained on a mandated
repeat sample within 1 week. Vitamin B12 levels are monitored
annually; participants in whom levels fall below 150 pmol/L are
offered the choice of treatment discontinuation or referral back to
primary care for injectable supplements.
In addition to serious adverse event reporting, specific gastroin-
testinal, neurological, metabolic, renal and cardiovascular adverse
events of medical interest are also recorded, as well as new diabetes-
related complications, operations or procedures.
Following each meeting of the IDMC (see above), a recommen-
dation is made to the co-sponsors regarding the appropriateness of
continuing the trial, from a safety and efficacy perspective. In addi-
tion to these arrangements, a Glycaemia Committee led by Dr Irene
Hramiak (Ontario, Canada) sends detailed blinded reports of the parti-
cipants’ HbA1c status and rates of hypoglycaemia to each site every
6 months, along with “benchmarking” data from other sites in their
region. The Committee can contact and support centres in which
average HbA1c is higher than that in other comparable centres.
2.7 | Statistical considerations
All analyses will be conducted blinded to treatment allocation. The
principal analysis will be on a modified intention-to-treat analysis set,
ie, including all subjects from the intention-to-treat population (all
randomized participants, regardless of subsequent participation in the
study) with data available (without imputation). The target sample
size is based on analysis of cIMT primary endpoint data usingT
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repeated measures regression analysis, assuming a linear progression
in the control arm of mean 0.044 mm and SD 0.050 mm over
3 years.23 Regression model effect estimates with 95% confidence
intervals and associated P values will be calculated. In order to mini-
mize the residual SD, cIMT data will be adjusted for baseline cIMT as
well as for age, sex and baseline levels of cardiovascular risk factors
predictive of cIMT progression (specified in the Statistical Analysis
Plan). To account for differences in ultrasound machines used at sites,
a sensitivity analysis adjusting for ultrasound probe frequency is also
specified along with a separate per protocol analysis.
A final sample size of 200 participants per treatment arm provides
90% power to detect an average mean cIMT difference of at least
0.0167 mm (one third of an SD) between treatment arms (α = 0.05);
we therefore aim to recruit 500 patients allowing for 20% treatment
withdrawal and/or treatment discontinuation. This sample size will
provide 90% power to detect differences of approximately 0.3 SD in
secondary endpoints including lipid, metabolic and endothelial func-
tion (α = 0.05). The retinopathy secondary endpoint is exploratory; if
3-year 2-step progression in the ETDRS category is estimated at
13.7%, treatment with metformin will necessarily be associated with a
60% reduction in risk for 80% power to declare significance at
P < 0.05. No interim analyses are planned or pre-specified.
3 | RESULTS AND DISCUSSION
REMOVAL is the first adequately-powered long-term trial addressing
the impact of metformin on a valid CV surrogate outcome (cIMT) in
T1D. It will also collect data on metabolic endpoints (insulin dose,
weight, HbA1c, hypoglycaemia, LDL cholesterol) as well as other vas-
cular outcomes (endothelial function, retinal disease).
Metformin is a biguanide that undergoes active transport via cat-
ionic transporters and accumulates in intestinal cells.24 During
steady-state oral therapy, plasma glucose is reduced mainly by inhibi-
tion of hepatic glucose production.25 Glucose-lowering is key in redu-
cing microvascular complications in both T1D and T2D, but its effect
on cardiovascular (macrovascular) complications is more complex, as
other risk factors impact to a greater or lesser extent.
The differing molecular mechanisms of action of the various
available classes of glucose-lowering “antidiabetic” agents are criti-
cal to their overall therapeutic profile as candidates for adjunct
therapy. For metformin, mechanisms relevant to glucose-lowering
include activation of AMP-activated protein kinase (AMPK),26 inhibi-
tion of mitochondrial glycerophosphate dehydrogenase,27 and
release of gut hormones (including glucagon-like peptide-1).28 How-
ever, other downstream effects of AMPK have been postulated to
mediate vascular actions of metformin,29 including modulation of
proinflammatory pathways in perivascular adipose tissue30 and inhi-
bition of STAT3 (and thereby monocyte to macrophage differentia-
tion) in vascular tissue.31 Moreover, metformin can inhibit advanced
glycosylation end product (AGE) formation by binding and inactivat-
ing methyglyoxal via an AMPK-independent pathway.32
The primary focus of REMOVAL is to assess metformin’s effects
on the cardiovascular system in adults with T1D who are at high risk
of CV disease, rather than its ability to lower glucose levels.
Accordingly, we adopted a double-blind, placebo-controlled, “treat to
target HbA1c” design. When adjunct agents are prescribed in T1D,
insulin doses are often down-titrated to avoid hypoglycaemia, such that
an overall effect on glycaemia (measured by HbA1c) is not sus-
tained.10,11,13 Thus, although HbA1c is 1 of 7 pre-specified secondary
endpoints, it is unlikely, by design, that a sustained separation in glycae-
mia between active and placebo arms will be observed. Instead, the trial
is powered to detect whether 3 years of treatment with metformin
reduces atherosclerosis progression as measured by cIMT. In addition
to measuring vascular structure, we are assessing endothelial function
(RHI) in 80% of participants, to provide an index of vascular function.
cIMT can be considered a validated surrogate endpoint for ather-
osclerotic disease in T1D on the basis of DCCT-EDIC.3,18 However,
despite the variety of pathways by which metformin has been
hypothesized to exert potentially beneficial effects on the cardiovas-
cular system, 29–31 there is conflicting evidence regarding its effects
on cIMT. We recently reported that metformin had no impact on cIMT
over 18 months in non-diabetic patients with established coronary
heart disease33; similarly, no reduction in cIMT progression was
detected in insulin-treated people with T2D in the recent (underpow-
ered) Copenhagen IMT trial.34 However, metformin has been reported
to reduce cIMT progression in metabolic syndrome35 and also in
T2D.36 REMOVAL is the first cIMT progression trial concerning T1D;
in this context it is important to note that mechanisms of accelerated
atherosclerosis in T1D and T2D differ in a number of aspects.37,38
Despite a paucity of evidence concerning T1D, metformin
(embonate) already holds a product license for use in T1D in
France39; moreover, the UK National Institute for Clinical Excellence
(NICE) recently recommended metformin for adults with T1D and
BMI ≥ 25 kg/m2 who “want to improve glucose control while mini-
mising their effective insulin dose.”40 Currently, more than 50% of
people with T1D are now obese or overweight.8 Given that
REMOVAL is planned to be 3 times longer and larger than any previ-
ous T1D metformin trial, the secondary endpoint data will be of con-
siderable clinical utility in addressing longer term metabolic effects
(eg, those on weight and insulin dose).
As metformin is structurally related to phenformin, which was
withdrawn in the 1970s because of cases of lactic acidosis, concerns
have been expressed regarding its use in ketoacidosis-prone T1D
patients.41 Metformin is commonly associated with gastrointestinal
adverse effects, and long-term use in T2D is associated with vitamin
B12 deficiency.42,43 Rather than simply extrapolating its adverse
effect profile and overall tolerability from T2D, REMOVAL will gather
important specific safety data on metformin in T1D.
A key limitation of the study is use of a surrogate primary end-
point rather than clinical cardiovascular events.44 Although several
large T2D CV outcome trials have been reported recently and many
more are in progress,45 not a single randomized trial of any interven-
tion with CVD as the primary outcome has been performed in T1D
to date, despite the undoubted impact of CV disease in this condi-
tion.1,2 Much of the current evidence base for CV preventive strate-
gies in T1D (including that for statins) is extrapolated from T2D or
from meta-analysis of T1D subgroups.46,47 Another limitation is that
focusing on atherosclerosis progression in the carotid artery may
obviate detection of any beneficial cardiovascular effects mediated
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by other mechanisms. Data on which to base estimates of the degree
of cIMT disease and the rate of change in our population were lim-
ited (mainly from DCCT); thus, there remains a degree of uncertainty
in the power of a 3-year intervention study in this population. Finally,
the retinal endpoint can be regarded only as exploratory; it was
included to acquire a point estimate for any likely effect size to guide
future research, given the relatively low marginal cost of acquiring
images from routine screening (at least at UK sites).
Two different glucose-lowering agents used in T2D have recently
been demonstrated to improve cardiovascular outcomes: a GLP-1
agonist48 and an SGLT2 inhibitor.49 We anticipate that our interna-
tional effort in REMOVAL, the largest and longest clinical trial of
adjunct metformin therapy concerning T1D to date, will illustrate the
feasibility of conducting large collaborative multi-centre cardiovascu-
lar trials of adjunct therapy in T1D. Whether the data for metformin in
the REMOVAL trial are positive or negative, we hope they will provide
a stimulus to funding agencies and the wider diabetes community to
support timely trials of other adjunct therapy candidates, with the twin
aims of improving metabolic control and CV outcomes. Agents that
are able to reduce rates of CV disease are urgently needed in T1D.
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